Cargando…

Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy

SIMPLE SUMMARY: Although the introduction of programmed cell death 1 (PD-1) immune checkpoint inhibitors (ICIs) has significantly improved the overall survival (OS) in patients with metastatic melanoma, a substantial number of patients do not benefit from ICIs. Therefore, the predictive value of sin...

Descripción completa

Detalles Bibliográficos
Autores principales:	de With, Mirjam, Hurkmans, Daan P., Oomen-de Hoop, Esther, Lalouti, Ayoub, Bins, Sander, El Bouazzaoui, Samira, van Brakel, Mandy, Debets, Reno, Aerts, Joachim G. J. V., van Schaik, Ron H. N., Mathijssen, Ron H. J., van der Veldt, Astrid A. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002987/ https://www.ncbi.nlm.nih.gov/pubmed/33803602 http://dx.doi.org/10.3390/cancers13061370

Ejemplares similares

Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
por: Hurkmans, Daan P., et al.
Publicado: (2020)

Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
por: Bins, Sander, et al.
Publicado: (2018)

CD45RA(+)CCR7(−) CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
por: Kunert, Andre, et al.
Publicado: (2019)

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
por: Hurkmans, Daan P., et al.
Publicado: (2019)

Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients
por: Agema, Bram C., et al.
Publicado: (2020)

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
por: de With, Mirjam, et al.
Publicado: (2023)

Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient
por: Siddiqui, Imran, et al.
Publicado: (2016)

Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis
por: ten Berge, Deirdre M.H.J., et al.
Publicado: (2019)

Treatment and Implications of Vascular Endothelial Growth Factor Inhibitor‐Induced Blood Pressure Rise: A Clinical Cohort Study
por: van Dorst, Daan C. H., et al.
Publicado: (2022)

Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen
por: Hussaarts, Koen G.A.M., et al.
Publicado: (2019)

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
por: de Man, Femke M., et al.
Publicado: (2018)

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
por: Hurkmans, Daan P., et al.
Publicado: (2021)

Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment
por: Hurkmans, Daan P., et al.
Publicado: (2019)

Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report
por: de Joode, Karlijn, et al.
Publicado: (2023)

CYP3A4(∗)22 Genotyping in Clinical Practice: Ready for Implementation?
por: Mulder, Tessa A. M., et al.
Publicado: (2021)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma
por: Hurkmans, Daan P, et al.
Publicado: (2020)

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients
por: Bins, Sander, et al.
Publicado: (2018)

Feasibility of Extrapolating Randomly Taken Plasma Samples to Trough Levels for Therapeutic Drug Monitoring Purposes of Small Molecule Kinase Inhibitors
por: van Eerden, Ruben A. G., et al.
Publicado: (2021)

Lack of B and T cell reactivity towards IDH1(R132H) in blood and tumor tissue from LGG patients
por: Weenink, Bas, et al.
Publicado: (2019)

T Cells Expressing a TCR-Like Antibody Selected Against the Heteroclitic Variant of a Shared MAGE-A Epitope Do Not Recognise the Cognate Epitope
por: Saeed, Mesha, et al.
Publicado: (2020)

Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer
por: Veerman, G.D. Marijn, et al.
Publicado: (2023)

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu
por: Kunert, Andre, et al.
Publicado: (2013)

Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer
por: Hurkmans, Daan P, et al.
Publicado: (2020)

Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody
por: Saeed, Mesha, et al.
Publicado: (2016)

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
por: Mulder, Tessa A. M., et al.
Publicado: (2021)

Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients
por: de Man, Femke M., et al.
Publicado: (2019)

Tumor mutational load, CD8(+) T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
por: Hurkmans, Daan P., et al.
Publicado: (2020)

Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension
por: van Doorn, Leni, et al.
Publicado: (2022)

The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2019)

TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune Targets
por: Straetemans, Trudy, et al.
Publicado: (2012)

Reduced glucose concentration enhances ultradian rhythms in Pdcd5 promoter activity in vitro
por: Ting, Isaiah J., et al.
Publicado: (2023)

Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer
por: van Eerden, Ruben A. G., et al.
Publicado: (2021)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2020)

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer
por: Rijnders, Maud, et al.
Publicado: (2022)

Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment
por: Buck, Stefan A. J., et al.
Publicado: (2022)

Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer
por: Steendam, Christi M. J., et al.
Publicado: (2020)

Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel
por: van Doorn, Leni, et al.
Publicado: (2021)

Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl
por: Kuip, Evelien J.M., et al.
Publicado: (2018)

CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients
por: van Eerden, Ruben A. G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b596qk7ecdpnbcsnopse8tq2mo